The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa
Research output: Contribution to journal › Letter › Research › peer-review
Documents
- Fulltext
Accepted author manuscript, 203 KB, PDF document
Original language | English |
---|---|
Journal | British Journal of Dermatology |
Volume | 187 |
Issue number | 2 |
Pages (from-to) | 274-274 |
ISSN | 0007-0963 |
DOIs | |
Publication status | Published - 2022 |
Bibliographical note
Conflicts of interest: H.C.R. has received research funding from the Kgl Hofbundtmager Aage Bang Foundation and honoraria as speaker from LEO Pharma. S.F.T. has been a speaker and/or served on advisory boards for AbbVie, Almirall, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB, and has received research support from AbbVie, Janssen, LEO Pharma, Novartis, Sanofi and UCB.
ID: 313866645